Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • JenyaD
    Junior Member
    • Mar 2018
    • 2

    chip-seq data analysis with galaxy

    Hi all! I am very new to this field, so I apologize in advance for my ignorance. I have done several chip-seq experiments on a protein from A.thaliana that functions in homologous recombination. I am struggling a lot with analyzing my data, mostly because I do not completely understand how the tools work. I use galaxy to do the analysis, Bowtie and MACS.

    I have several questions regarding these tools, hopefully someone will help!
    1. I know MACS provides the peak scores as -10log(pvalue) and it gives me ranges usually from 50-3100. But how does MACS2 calculate the score? Using the same dataset, I get very narrow ranges usually in single digits.
    2. What do treatment wig and control wig files show? I read that they show the binding signal, however this explanation is way to vague for me. And how can I correlate the peak bed file to the bigwig file on a genome browser?
    3. When I use MACS to call the peaks, I use default setting (pvalue cutoff 1e-5, and MFOLD value of 32). However, MACS fails everytime since it cannot find enough paired peaks to build the shifting model. Lowering the MFOLD value does not help. Only when I choose not to build the shifting model, only then will MACS succeed in calling the peaks. But, now I am worried, can I trust these peaks that MACS called? If it cannot make a shifting model, how could I predict the location of the binding site? I leave the arbitrary shift size 100 bp, but how do I know if this is the proper value to use? I also read that MACS cannot build the shifting model since there is no defined peaks, this can be a result of broad peaks (like for RNApol), it looks like my peaks are broad as well.

    Thank you for your help!!!!

Latest Articles

Collapse

  • SEQadmin2
    Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
    by SEQadmin2


    Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

    The systematic characterization of the human proteome has
    ...
    07-20-2026, 11:48 AM
  • SEQadmin2
    Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
    by SEQadmin2



    Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
    ...
    07-09-2026, 11:10 AM
  • SEQadmin2
    Cancer Drug Resistance: The Lingering Barrier to Rising Survival
    by SEQadmin2



    Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

    There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
    07-08-2026, 05:17 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, Yesterday, 12:17 PM
0 responses
13 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-23-2026, 11:41 AM
0 responses
14 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-20-2026, 11:10 AM
0 responses
23 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-13-2026, 10:26 AM
0 responses
37 views
0 reactions
Last Post SEQadmin2  
Working...